media – Page 805 – Pharma & Medical Industry Insights Hub | Drugdu Insights & Updates

Illumina and Loxo Oncology to Partner on Developing Next-Generation Sequencing-Based Pan-Cancer Companion Diagnostics

Illumina, Inc. (Nasdaq: ILMN) and Loxo Oncology (Nasdaq: LOXO) today announced a global strategic partnership to develop and commercialize a multi-gene panel for broad tumor profiling, resulting in a distributable, next-generation sequencing (NGS) based companion diagnostic (CDx) with a pan-cancer indication.
- Source: Illumina
- 927
- April 12, 2018
larotrectinib Market Views
Alexion to buy Wilson for $855m

Alexion Pharmaceuticals has offered to buy Wilson Therapeutics in a deal worth around $855 million. Wilson is a Swedish biopharma developing novel therapies for patients with rare copper-mediated disorders.
- Source: pharmatimes
- 784
- April 12, 2018
Alexion Market Views rare copper-mediated disorders
Novartis’ Afinitor Disperz wins new TSC-related approval

Novartis’ Afinitor Disperz has become the first medicine to be specifically approved by US regulators to treat patients aged two years and above with tuberous sclerosis complex (TSC)-associated partial-onset seizures.
- Source: pharmatimes
- 1,109
- April 12, 2018
Afinitor Disperz New Approvals Novartis TSC
Ionis and AstraZeneca Advance New Drug for NASH

Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), the leader in antisense therapeutics, today announced that it has licensed IONIS-AZ6-2.5-LRx, or AZD2693, to AstraZeneca (NYSE: AZN) following advancement of the drug into development. IONIS-AZ6-2.5-LRx is designed to inhibit an undisclosed target to treat patients with nonalcoholic steatohepatitis (NASH)
- Source: Prnewswire
- 1,078
- April 11, 2018
Market Views NASH
FDA restricts sales of a Bayer’s Essure birth control device

The Food and Drug Administration(FDA) moved Monday to put sales restrictions on a Bayer birth control implant that has been a target of consumer criticism.
- Source: Usatoday
- 950
- April 11, 2018
Company Insights contraceptive device
FDA Approves Rucaparib for Maintenance Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

On April 6, 2018, the Food and Drug Administration(FDA) approved rucaparib (Rubraca®, Clovis Oncology Inc.), a poly ADP-ribose polymerase (PARP) inhibitor, for the maintenance treatment of recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy.
- Source: asco.org
- 867
- April 11, 2018
FDA New Approvals rucaparib
U.S. Food and Drug Administration Accepts for Priority Review Bristol-Myers Squibb’s Application for Opdivo (nivolumab) in Previously Treated dMMR or MSI-H Metastatic Colorectal Cancer

Application based on results from Phase 2 CheckMate -142 study
- Source: investors.bms
- 1,034
- April 11, 2018
Bristol-Myers Squibb FDA New Approvals Opdivo
The top 5 mental/behavioural health startups that have raised funding

Healthcare is such a massive space, one that takes up a sixth of the entire U.S. economy, that just one small piece of that pie can be extremely lucrative. Take diabetes, for example, where there has been a slew of different companies tackling that problem, and raising money in the process, including Glooko, Omada Health, Siren and Virta Health.
- Source: VatorNews
- 1,777
- April 11, 2018
Market Views Mental health mHealth
App accurately tracks Parkinson’s disease symptoms

Capturing a patient’s experience outside the doctor’s office has been an ongoing struggle when it comes to treating Parkinson’s disease. But now a new smartphone app can now detect the severity of symptoms in patients with Parkinson’s disease remotely, according to a recent study published by JAMA.
- Source: MobiHealthNews
- 1,069
- April 11, 2018
mHealth Parkinson’s disease Researches
Outcome Health pays $2.9M to resolve class-action lawsuit over unwanted texts to patients

Fresh off accusations of fraud from its own investors, Outcome Health has agreed to pay $2.9 million to settle a class-action lawsuit claiming the company continued to send automated text messages to users despite repeated requests to opt out of the service.
- Source: FierceHealthcare
- 1,112
- April 11, 2018
Company Insights digital health

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.